Efficacy and safety of apalutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a subgroup analysis of a randomized, double-blind, placebo-controlled, Phase-3 study

BACKGROUND: In the global Phase-3 Selective Prostate Androgen Receptor Targeting with ARN-509 study, apalutamide plus ongoing androgen deprivation therapy (ADT) significantly increased metastasis-free survival (MFS) and improved other clinical outcomes in men with nonmetastatic castration-resistant...

Descripción completa

Detalles Bibliográficos
Autores principales: Uemura, Hiroji, Satoh, Takefumi, Tsumura, Hideyasu, Arai, Gaku, Imanaka, Keiichiro, Shibayama, Kazuhiro, Fujii, Koji, Rooney, Brendan, Lopez-Gitlitz, Angela, Espina, Byron, Perez-Ruixo, Carlos, Small, Eric J., Smith, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Asian Pacific Prostate Society 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767934/
https://www.ncbi.nlm.nih.gov/pubmed/33425798
http://dx.doi.org/10.1016/j.prnil.2020.05.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7767934/
https://www.ncbi.nlm.nih.gov/pubmed/33425798
http://dx.doi.org/10.1016/j.prnil.2020.05.002

Ejemplares similares